We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Mechanical Circulatory Pump Supports Failing Hearts

By HospiMedica International staff writers
Posted on 27 Aug 2015
An acute cardiac assist device reduces end-diastolic pressure, end-diastolic volume, and the oxygen demand of the myocardium.

The HeartMate Percutaneous Heart Pump (PHP) is an axial vector flow pump designed to quickly stabilize hemodynamically compromised patients by increasing blood flow. The device is comprised of an elastomeric, collapsible impeller and cannula driven by an external motor via a flexible drive shaft. It is delivered via percutaneous access through the femoral artery using a low-profile 14F introducer sheath and is advanced into the left ventricle, where it is unsheathed and is fully expanded to 24F, allowing for near-full physiological mean blood flow rates.

Image: The HeartMate Percutaneous Heart Pump (PHP) device (Photo courtesy of Thoratec).
Image: The HeartMate Percutaneous Heart Pump (PHP) device (Photo courtesy of Thoratec).

With a typical operating range of 17,000–20,000 revolutions per minute (RPM), the PHP is capable of generating an average blood flow of four to five liters per minute, nearing the physiological capacity of the heart. Other feature designed for hemocompatibility include low shear stress on the blood cells, an internal driveline constructed of 10 interwoven microcables for maximum durability, and a compact, lightweight console with a user-friendly touch-screen interface.

The HeartMate PHP is a product of Thoratec (Pleasanton, CA, USA), and has received the European Community CE mark of approval. The company has also received unconditional approval from the US Food and Drug Administration (FDA) for an IDE clinical trial in patients undergoing high-risk percutaneous coronary interventions.

“PHP is an entirely new opportunity for Thoratec,” said D. Keith Grossman, President and CEO of Thoratec. “Although the current catheter pump market outside the US is relatively small, we look forward to gaining valuable clinical and commercial experience through a targeted European launch of HeartMate PHP in the coming months.”

Related Links:

Thoratec
Heartmate Video 



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Anesthesia Cart
UMGSA-33369-VIL

Latest Critical Care News

AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases

Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time

Wearable Multiplex Biosensors Could Revolutionize COPD Management